Advances in Pharmacogenomic Research and Development

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 25, Issue 3, 2003, Pages 275-281

  McCarthy, Jeanette J ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

Drug; Genetic; Pharmacogenomic; Polymorphism

Indexed keywords

DNA;

DATA BASE; DNA POLYMORPHISM; DRUG RESPONSE; GENETIC EPIDEMIOLOGY; GENETIC MARKER; HUMAN GENOME; MEDICAL RESEARCH; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; SEQUENCE ANALYSIS;

GENETIC MARKERS; GENOME, HUMAN; HUMANS; LINKAGE DISEQUILIBRIUM; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RESEARCH; TECHNOLOGY, PHARMACEUTICAL;

EID: 0242487713     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:25:3:275     Document Type: Review

References (29)

1. Hirschhorn, J. N., Lohmueller, K., Byrne, E., and Hirschhorn, K. A. (2002) Comprehensive review of genetic association studies. Genet. Med. 4, 45-61.
2. Brower, V. (1998) Genome II: the next frontier. Nat. Biotechnol. 16, 1004.
3. Marshall, E. (1999) Drug firms to create public database of genetic mutations. Science 284, 406-407.
4. McCarthy, J. J. and Hilfiker, R. (2000) The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat. Biotechnol. 18, 505-508.
5. Chin, K. V. and Kong, A. N. (2002) Application of DNA microarrays in pharmacogenomics and toxicogenomics. Pharm. Res. 19, 1773-1778.
6. Lander, E. S., Linton, L. M., Birren, B., et al. (2001) Initial sequencing and analysis of the human genome. Nature 409, 860-921.
7. Cargill, M., Altshuler, D., Ireland, J., et al. (1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22, 231-238.
8. Loots, G. G., Locksley, R. M., Blankespoor, C. M., et al. (2000) Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. Science 288, 136-140.
9. Gabriel, S. B., Schaffner, S. F., Nguyen, H., et al. (2002) The structure of haplotype blocks in the human genome. Science 296, 2225-2229.
10. Drysdale, C. M., McGraw, D. W., Stack, C. B., et al. (2000) Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97, 10,483-10,488.
11. Lavori, P. W., Krause-Steinrauf, H., Brophy, M., et al. (2002) Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study. Control. Clin. Trials. 23, 222-239.
12. Lohmueller, K. E., Pearce, C. L., Pike, M., Lander, E. S., and Hirschhorn, J. N. (2003) Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33, 177-182.
13. Wacholder, S., Rothman, N., and Caporaso, N. (2000) Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J. Natl. Cancer Inst. 92, 1151-1158.
14. Pritchard, J. K. and Rosenberg, N. A. (1999) Use of unlinked genetic markers to detect population stratification in association studies. Am. J. Hum. Genet. 65, 220-228.
15. Reich, D. E. and Goldstein, D. B. (2001) Detecting association in a case-control study while correcting for population stratification. Genet. Epidemiol. 20, 4-16.
16. Arranz, M. J., Munro, J., Sham, P., et al. (1998) Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr. Res. 32, 93-99.
17. Ioannidis, J. P., Trikalinos, T. A., Ntzani, E. E., and Contopoulos-Ioannidis, D. G. (2003) Genetic associations in large versus small studies: an empirical assessment. Lancet 361, 567-571.
18. Ioannidis, J. P., Rosenberg, P. S., Goedert, J. J., and O'Brien, T. R. (2002) Commentary: meta-analysis of individual participants' data in genetic epidemiology. Am. J. Epidemiol. 156, 204-210.
19. McCusker, S. M., Curran, M. D., Dynan, K. B., et al. (2001) Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet. 357, 436-439.
20. Arranz, M. J., Munro, J., Birkett, J., et al. (2000) Pharmacogenetic prediction of clozapine response. Lancet. 355, 1615-1616.
21. Lesko, L. J. and Woodcock, J. (2002) Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J. 21), 20-24.
22. Testing DoHaHSSsACoG. (2000) Fed. Regist. 65, 77,631.
23. Hodgson, J. (2000) First genetic trust banks on genes. Nat. Biotechnol. 18, 1236.
24. Secretary's Advisory Committee on Genetics HaS. Available at http://www4.od.nih.gov/oba/sacghs.htm). Accessed on November 23, 2002.
25. Arranz, M., Collier, D., Sodhi, M., et al. (1995) Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346, 281-282.
26. Malhotra, A. K., Goldman, D., Ozaki, N., Breier, A., Buchanan, R., and Pickar, D. (1996) Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am. J. Psychiatry 153, 1092-1094.
27. Masellis, M., Paterson, A. D., Badri, F., et al. (1995) Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 346, 1108.
28. Nothen, M. M., Rietschel, M., Erdmann, J., et al. (1995) Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 346, 908-909.
29. Nimgaonkar, V. L., Zhang, X. R., Brar, J. S., DeLeo, M., and Ganguli, R. (1996) 5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected. Psychiatr. Genet. 6, 23-27.